AstraZeneca reports first-half growth, disappointment in Ultomiris trial
27th Jul 2026 09:10
(Sharecast News) - AstraZeneca reported first-half total revenue of $30.7bn on Monday, up 9%, while core earnings per share increased 12% to $5.21 as double-digit growth in its Oncology and Rare Disease businesses offset headwinds from Farxiga's US loss of exclusivity and China's volume-based procurement programme.
Read moreAstraZeneca breast cancer drug receives EU approval
23rd Jul 2026 12:28
(Sharecast News) - A breast cancer drug developed by AstraZeneca has been approved in the European Union for the treatment of certain types of the disease, the pharmaceutical giant announced on Thursday.
Read moreAstraZeneca shares slide on failure of cardiomyopathy trial
9th Jul 2026 09:57
(Sharecast News) - AstraZeneca said on Thursday that the phase 3 CARDIO-TTRansform trial of Wainua in adults with transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, failing to show a statistically significant benefit against placebo on the composite measure of cardiovascular mortality and recurrent cardiovascular clinical events up to 140 weeks.
Read moreAstraZeneca's Datroway and Enhertu candidates receive EU approval
29th Jun 2026 07:07
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first‑line monotherapy for adults with unresectable or metastatic triple‑negative breast cancer who are not eligible for PD‑1/PD‑L1 inhibitor treatment.
Read moreAstrazeneca's Imfinzi receives green light from US FDA
29th May 2026 07:21
(Sharecast News) - Drugmaker Astrazeneca said on Friday that Imfinzi has been approved in the US as part of the first immunotherapy‑based combination for patients with high‑risk, non‑muscle‑invasive bladder cancer who have not previously been treated with Bacillus Calmette-Guérin.
Read moreUS FDA pushes back decision on Astrazeneca's camizestrant
27th May 2026 09:01
(Sharecast News) - Drugmaker Astrazeneca said the US Food and Drug Administration had pushed back its decision on camizestrant after requesting additional data for the drug's new application.
Read moreAstrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations
26th May 2026 08:16
(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that its breast cancer treatment camizestrant has secured EU approval, while its Enhertu and Datroway drug candidates also received fresh regulatory recommendations in Europe and the US.
Read moreCiti sees buying opportunity at AstraZeneca after recent falls
18th May 2026 11:21
(Sharecast News) - Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-quarter earnings season.
Read moreAstraZeneca secures US approval for two drugs
18th May 2026 09:06
(Sharecast News) - Two AstraZeneca drugs have been given the green light in America to treat high blood pressure and breast cancer, the blue chip confirmed on Monday.
Read moreLondon close: Stocks mixed as investors mull longer Hormuz blockade
1st May 2026 14:13
(Sharecast News) - London stocks ended mixed on Friday as investors weighed ongoing concerns about the Strait of Hormuz blockade against resilient domestic data, after the Bank of England warned that inflation could breach 6% next year in a worst-case scenario linked to higher oil prices.
Read moreAstraZeneca Q1 revenues grow, reiterates FY26 constant currency guidance
29th Apr 2026 07:16
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that it had delivered solid revenue growth and a series of positive late‑stage trial readouts in the first quarter, reinforcing confidence in its 2030 ambitions.
Read moreAstraZeneca's asthma maintenance treatment receives US FDA approval
28th Apr 2026 07:11
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it asthma maintenance treatment Breztri Aerosphere had received approval from the US Food and Drug Administration for adults and adolescents aged 12 and over.
Read moreAstraZeneca's Saphnelo Pen gets green light from US FDA
27th Apr 2026 07:12
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its systemic lupus erythematosus treatment Saphnelo (anifrolumab) hsd received US Food and Drug Administration approval for self‑administration via a once‑weekly autoinjector, the Saphnelo Pen.
Read moreAstraZeneca receives positive high level results from Phase III I CAN trial
21st Apr 2026 07:07
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that high‑level results from an interim analysis of its Phase III I CAN trial showed Ultomiris had met its primary endpoint, delivering a statistically significant and meaningful reduction in proteinuria in adults with IgA nephropathy at risk of disease progression.
Read moreAstraZeneca's COPD candidate succeeds in twin Phase III studies
27th Mar 2026 07:07
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its monoclonal antibody tozorakimab had met the primary endpoint in both of its Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease.
Read more